

Sale Process Details

On June 20, 2024, Atlas Global Brands Inc. and a number of its subsidiaries (collectively "Atlas Global" or "the Company") filed for creditor protection under the Companies' Creditors Arrangement Act (Canada) ("CCAA") to enable it to restructure its affairs, including by soliciting a sale or an investment in the Company through a sale or investment solicitation process ("SISP"). Ernst & Young Inc. was appointed monitor (the "Monitor") in the CCAA proceedings. The Monitor is assisting Atlas Global in running the SISP to source an investment, recapitalization and/or a sale of the business.



AQUISITION OPPORTUNITY: ATLAS GLOBAL BRANDS

CSE: **ATL**

Integrated domestic and international business with an indoor facility in Stratford, Ontario (with capacity of 3,500 kg/year) and an EU-GMP certified facility in Chatham, Ontario (with capacity of 6,500 kg/year with licensed capacity to expand to 9,500 kg/year), licensed nursery with genetic pipeline of cultivars, offering a combination of established portfolio of brands, solid domestic sales and a hub to leverage an existing export business with sales in 7 international markets, exclusive partnerships and high gross margins.



EU-GMP CULTIVATION | PROCESSING | PACKAGING | EXPORTING TO 7 INTERNATIONAL MARKETS

GLOBAL PLATFORM WITH EXPANSION POTENTIAL

EU-GMP GLOBAL SUPPLY CHAIN WITH BEST IN CLASS EXPORTING CAPABILITIES

- Accelerated (4 week) execution to export to all 7 international markets with permit and packaging on hand
- Expertise in compliance and regulatory protocols in international markets ensures consistent and accurate shipments

INTERNATIONAL PARTNERSHIPS WITH EXCLUSIVITY AGREEMENTS

- Established exclusivity agreements in Australia, Germany, United Kingdom, Denmark, Switzerland, Norway with minimum order quantities
- Existing international customers have demand exceeding current supply with significant growth potential on baseline business

HIGH GROSS MARGINS ACROSS ALL GLOBAL CANNABIS MARKETS

- No excise tax burden with an ability to drive further efficiencies in operations through increased production and throughput with key partners as Germany and other global markets continue to develop
- Opportunity to further increase margins with production efficiencies and increased sales in growing markets such as Germany and other developing markets



ATLAS GLOBAL BRANDS
SIGNS EXCLUSIVE
PARTNERSHIP WITH
SNOOP DOGG
TO LAUNCH
CANNABIS BRANDS
INTERNATIONALLY


EU-GMP LAUNCH READY PRODUCT PORTFOLIO



FLOWER



OIL DROPS



VAPES



CONCENTRATES



HASH

Atlas Global Brands is an established domestic and international business with GACP, IMC-GAP & EU-GMP certifications, making it one of the most sought-after export businesses in Canada. With proven expertise in compliance and regulatory protocols, Atlas' partners can rely on its global supply chain for the export of quality cannabis.

7

INTERNATIONAL
MARKETS

\$17.6M

INTERNATIONAL
SALES⁽¹⁾

\$31.2M

GLOBAL
ANNUAL
SALES⁽¹⁾

48%

ANNUALIZED
GROWTH RATE⁽²⁾

13%

ADJUSTED
EBITDA
(AGMEDICA)⁽²⁾⁽³⁾

3%

ADJUSTED
EBITDA
(GREENSEAL)⁽²⁾⁽³⁾

(1) Draft, unaudited and unfilled Fiscal 2024 Results

(2) Annualized Cumulative Average Growth rate over the 9 months ended December 31, 2023 as reported in financial statements filed on SEDAR

(3) These are non-GAAP financial measures and are not standardized financial measures under the financial reporting framework used to prepare the financial statements and might not be comparable to similar financial measures disclosed by other issuers

FOR A VIRTUAL TOUR OF ATLAS GLOBAL BRANDS [CLICK HERE](#)

STATE-OF-THE-ART FACILITIES

CHATHAM, ON

AgMEDICA
BIOSCIENCE INC.



- GACP, IMC-GAP certified for flower cultivation
- EU-GMP certified for cannabis flower and extract production, packaging and labelling
- 6,500 kg/year capacity with opportunity to expand by 3,000+ kgs/year with addition of equipment to fully built-out grow rooms
- Total facility square footage of ~110,000
- Owned and appraised at \$25-30M

STRATFORD, ON

GREENSEAL
CANNABIS CO.



- GACP certified for flower cultivation
- 3,500 kg/year flower production capacity with opportunity to expand by an additional 3,000+ kgs/annually
- Licensed nursery program to expand genetic pipeline for new cultivars
- Total facility square footage of ~30,000
- Owned and appraised at \$8.9M


ISRAELI PHARMACIES

- 51% ownership in 3 established pharmacies in prime Israel locations in Tel Aviv and Jerusalem
- 2 fully licensed to dispense cannabis with the other license pending MCU approval providing direct patient access

REVENUE PROJECTIONS & BALANCE SHEET INFORMATION


CONSOLIDATED FINANCIALS (\$M)

■ PHARMACY OPERATIONS ■ DOMESTIC SALES ■ INTERNATIONAL SALES




CY2023 H1 2024 H2 2024 CY 2024 CY 2025

CONSOLIDATED ASSETS



■ CURRENT ■ FIXED

CONSOLIDATED DEBT STACK



■ SECURED ■ UNSECURED

The information for CY 2024 and CY 2025 is future oriented financial information prepared as of July 29, 2024 and is based on the following assumptions: 1) continuation of existing operations as currently deployed with investment for working capital only; 2) continued growth of European market; and 3) no significant changes in the regulatory environment, each of which management believes to be reasonable. Actual results may vary from these projections.

KEY SISP MILESTONES

- **NON-BINDING LETTER OF INTENT DEADLINE: September 6, 2024**
- **FINAL BINDING BID DEADLINE: September 19, 2024**
- **TARGETED COURT APPROVAL DATE: September 26, 2024**

Interested parties submit non-binding LOI bid to: Greg.J.Adams@parthenon.ey.com

CONTACT

Interested parties are requested to contact one of the persons listed below. Access to relevant due diligence material will be made available to selected parties following signing of a non-disclosure agreement.

MIKE BELL
Senior Vice President
Ernst & Young Inc.
+1 604 899 3566
mike.bell@parthenon.ey.com

BERNIE YEUNG
Chief Executive Officer
Atlas Global Brands
bernie@atlasglobalbrands.com

DISCLAIMER

The information contained in this Overview is submitted to parties for use solely in connection with their consideration of the transaction opportunity described herein and is not to be reproduced or distributed. By its acceptance hereof, the recipient agrees that neither it nor any of its employees or advisors shall use the information for any purpose other than the evaluation of the transaction opportunity, nor shall it divulge the information or distribute this Overview to any other party, in whole or in part, at any time without the prior written consent of Atlas Global Brands Inc. through Ernst & Young Inc. The information contained herein, while obtained from sources which we believe to be reliable, has not been independently verified and no representation, express or implied, is given as to its accuracy or completeness.

Delivery of this Overview does not constitute an offer to sell or a solicitation of an offer to purchase securities under the securities laws of any jurisdiction, including the Securities Act of 1933, as amended, or any state securities laws, or a solicitation to enter into any other transaction. This Overview is not to be reproduced or distributed. More detailed information is available for review upon the signing of a non-disclosure agreement.

Ernst & Young Inc.
Assurance / Tax / Transactions / Advisory
© 2024 Ernst & Young - all rights reserved.
Proprietary and confidential. Do not distribute without written permission